Pfizer announces successful trials of COVID-19 pills: 89% effectiveness

    08 Nov 2021

    Pfizer showed COVID-19 cure. In clinical trials, an antiviral drug has been shown to reduce the risk of hospitalization by 89%. The company promises to provide all documents to the US regulator by the end of November.

    The American company Pfizer stated that the anti-coronavirus pill created by its specialists reduces the risk of death and hospitalization among vulnerable adult patients by 89%.

    Clinical trials were completed prematurely.

    Paxlovid (he name of the drug) is intended for the elderly and those with a higher risk of severe disease.

    Britain was the first in the world to approve a drug from Covid-19

    Already the second pill has appeared. Earlier this week, Britain (the world’s first) approved molnupiravir – tablets against COVID-19 from pharmaceutical companies Merck Sharp & Dohme та Ridgeback Biotherapeutics (MSD). We’ve written about it here.

    Clinical trials have shown that it halves the risk of hospitalization and death from coronavirus.

    Pfizer said it had stopped clinical trials early because the initial results were already very positive.

    Britain ordered 250,000 doses of Pfizer and 480,000 doses of Merck.

    Pfizer tablets work on the principle of a protease inhibitor that blocks the enzyme needed by the virus to reproduce. It works a little differently than the Merck tablet, which makes a mistake in the virus’s genetic code.

    Pfizer has said it plans to submit the results of interim trials of its drug to the U.S. Drug Regulatory Authority (FDA) as part of an emergency program it launched last month.

    UK to roll out COVID-19 antiviral drug trial this month – Health Security Agency

    Britain will start to roll out Merck’s molnupiravir COVID-19 antiviral pill through a drug trial later this month, Susan Hopkins, Chief Medical Adviser at the UK Health Security Agency, said on November 7.

    Last week Britain became the first country in the world to approve the potentially game-changing COVID-19 antiviral pill, jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics.

    The government said in October it had secured 480,000 courses of the Merck drug and 250,000 courses of an antiviral pill developed by Pfizer Inc (PFE.N). read more

    Asked about the molnupiravir approval, Hopkins told BBC television: “That is great news, and it will start to be rolled out through a drug trial at the end of this month/the beginning of December.”

    Hopkins said all the trials so far had been done with the unvaccinated, so this would help understand how it will work in the wider vaccinated population.

    “The new Pfizer drug is probably not going to be licensed until the new year sometime,” she added. “It is still likely to be a couple of months away.”

    Earlier, scientists have named the countries that may be the first to overcome the COVID-19 pandemic in 2022.

    Leave a Reply

    Your email address will not be published.